EYPT

EyePointA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$13.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$5.50

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$2.20

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Primary evidence is strong, but the thesis is now dominated by binary clinical risk. The August 17 LUGANO readout combined a full-dataset primary-endpoint miss with positive secondary endpoints [#SEC-8K-2026-08-17]. Recent packet headlines are negative; consolidated analyst revisions, options data, short interest, and social coverage are not robustly available. The peer set is limited to loose same-sector comparators, supporting monitoring rather than a high-conviction directional call.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-03catalystNear-term overhang after LUGANO resultHigh impact

LUGANO missed its primary endpoint in the full dataset, despite favorable secondary endpoints and an ad hoc non-inferiority analysis excluding an asymmetric cohort. This leaves continued uncertainty around regulatory interpretation and the second wet-AMD trial [#SEC-8K-2026-08-17].

2026-12-02eventLUCIA Phase 3 wet-AMD topline dataHigh impact

EyePoint expects LUCIA topline data in Q4 2026. The result should determine whether the LUGANO miss was isolated and is a key condition for a potential FDA NDA submission in the first half of 2027 [#SEC-8K-2026-08-17].

2027-09-03catalystDME pivotal readoutsHigh impact

COMO and CAPRI are fully enrolled with more than 480 patients; topline data are anticipated in Q4 2027, providing a longer-dated expansion opportunity beyond wet AMD [#SEC-8K-2026-08-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology